Comparison of Pluristem Therapeutics Inc. (PSTI) and Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

As Biotechnology companies, Pluristem Therapeutics Inc. (NASDAQ:PSTI) and Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics Inc. N/A 2153.20 27.98M -0.25 0.00
Ligand Pharmaceuticals Incorporated 251.45M 10.26 143.32M 8.82 16.84

We can see in table 1 the earnings per share, top-line revenue and valuation of Pluristem Therapeutics Inc. and Ligand Pharmaceuticals Incorporated.


Table 2 shows us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics Inc. 0.00% -91.6% -69.9%
Ligand Pharmaceuticals Incorporated 57.00% 32.3% 13.3%

Risk & Volatility

Pluristem Therapeutics Inc.’s 0.46 beta indicates that its volatility is 54.00% less volatile than that of Standard & Poor’s 500. Ligand Pharmaceuticals Incorporated on the other hand, has 1.55 beta which makes it 55.00% more volatile compared to Standard & Poor’s 500.


Pluristem Therapeutics Inc.’s Current Ratio is 3.3 while its Quick Ratio is 3.3. On the competitive side is, Ligand Pharmaceuticals Incorporated which has a 2.2 Current Ratio and a 2.2 Quick Ratio. Pluristem Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Ligand Pharmaceuticals Incorporated.

Analyst Ratings

Pluristem Therapeutics Inc. and Ligand Pharmaceuticals Incorporated Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Pluristem Therapeutics Inc. 0 0 0 0.00
Ligand Pharmaceuticals Incorporated 0 1 1 2.50

Competitively the consensus price target of Ligand Pharmaceuticals Incorporated is $263, which is potential 116.75% upside.

Institutional and Insider Ownership

The shares of both Pluristem Therapeutics Inc. and Ligand Pharmaceuticals Incorporated are owned by institutional investors at 5.1% and 0% respectively. 7.37% are Pluristem Therapeutics Inc.’s share held by insiders. Comparatively, 2.1% are Ligand Pharmaceuticals Incorporated’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pluristem Therapeutics Inc. -8.61% -16.36% -26.34% -29.5% -33.76% -28.48%
Ligand Pharmaceuticals Incorporated -5.8% -8.81% -42.02% -22.84% 12.91% 8.54%

For the past year Pluristem Therapeutics Inc. has -28.48% weaker performance while Ligand Pharmaceuticals Incorporated has 8.54% stronger performance.


Ligand Pharmaceuticals Incorporated beats Pluristem Therapeutics Inc. on 9 of the 11 factors.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.